Berlin-based Quantune, a deep tech startup in optics and photonics technology, announced on Tuesday that it has secured €13.5M in seed financing round.
Out of the total, the company raised €8.5M in equity financing, led by U.S.-based Point72 Ventures and Munich-based Vsquared Ventures.
This funding comes on top of more than €5M in public grants from the European Innovation Council (EIC) and the Investment Bank of Berlin (IBB) through the ProFIT program.
“Our vision is to change the way we think about health. This seed round enables us to embark on the exciting R+D, and productisation works ahead of us,” said Co-Founder Jan F. Kischkat.
Fund utilisation
The German company will use the funds to support product development to meet regulatory standards toward global market entry.
Additionally, the company will use the capital to expand its detection capabilities and fine-tune the spectrometer’s design for even better compactness and user experience.
Quantune Technologies will use the investment to focus on hiring top talent across nearly all departments.
“We are excited about the journey ahead and thrilled to have the backing of strong investors that reflect our global ambitions”, says co-founder Nikolaus Hahne.
Quantune Technologies: Developing continuous health monitoring wearable.
Founded in 2019 by Nikolaus Hahne and Jan F. Kischka, Quantune Technologies has developed a miniaturized laser spectrometer for continuous, non-invasive health monitoring.
Based on Quantune’s patented Quantum-Cascade Laser spectrometer, the wrist-worn device provides lab-quality precision in measuring biomarkers like glucose, lactate, and ketone bodies, making proactive and personalised healthcare accessible to all.
With over 40 patents in optics and photonics across 10 countries, Quantune is at the forefront of the development of mobile, real-time health monitoring solutions.
The investor
Point72 Ventures is a global venture capital strategy that invests in founders with bold ideas who use the latest technologies to drive transformational change across industries.
The VC offers entrepreneurs access to expertise and insights, executive and technical talent, and hands-on support.
“Creating a consumer wearable to monitor molecular biomarkers non-invasively has been a long-standing challenge. We think past approaches were inhibited by mature technologies with low data quality and heavy data processing,” says Tara Stokes, Partner at Point72 Ventures.
“We believe success lies in new technology with higher data quality from the start. It’s why we were so excited about Quantune. The founding team’s deep knowledge and vision for global impact have inspired us,” Stokes.
Investing in deep tech companies, Vsquared Ventures focuses on new space, new computing, energy transition, robotics and manufacturing, new computing and sensing, AI and next-gen software and tech-bio.
Vsquared Ventures has built one of Europe’s strongest deep tech portfolios, including industry disruptors Isar Aerospace, IQM Quantum Computing, Zama.ai, Customcells, Neura Robotics and The Exploration Company.
“Quantune Technologies’ approach to non-invasive health monitoring is a game-changer for chronically ill patients and health-conscious individuals alike,” says Michael Jobst, Principal at Vsquared Ventures. “Their technology is not only incredibly precise but also easily wearable,
opening up new possibilities for preventive and personalised healthcare.”
01
Not solo: How Xolo aims to help Dutch solopreneurs with its comprehensive business management platform